Active, not recruitingPhase 3NCT03762850
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
Studying IgA Nephropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Travere Therapeutics, Inc.
- Principal Investigator
- Radko Komers, MD, PhD, M.DTravere Therapeutics, Inc.
- Intervention
- sparsentan(drug)
- Enrollment
- 406 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2026
Study locations (30)
- Travere Investigational Site, Birmingham, Alabama, United States
- Travere Investigational Site, Homewood, Alabama, United States
- Travere Investigational Site, Glendale, California, United States
- Travere Investigational Site, Montebello, California, United States
- Travere Investigational Site, Northridge, California, United States
- Travere Investigational Site, San Diego, California, United States
- Travere Investigational Site, Stanford, California, United States
- Travere Investigational Site, Denver, Colorado, United States
- Travere Investigational Site, Coral Springs, Florida, United States
- Travere Investigational Site, Hollywood, Florida, United States
- Travere Investigational Site, Miami, Florida, United States
- Travere Investigational Site, Winter Park, Florida, United States
- Travere Investigational Site, Lawrenceville, Georgia, United States
- Travere Investigational Site, Nampa, Idaho, United States
- Travere Investigational Site, Hinsdale, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03762850 on ClinicalTrials.govOther trials for IgA Nephropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07182227PS-002 for the Treatment of IgA Nephropathy in AdultsPurespring Therapeutics Limited
- RECRUITINGPHASE3NCT07390123Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANHaisco Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE3NCT06994845Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgANNovartis Pharmaceuticals
- RECRUITINGPHASE2NCT07305974A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA NephropathyRigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
- RECRUITINGPHASE4NCT07030894Nefecon and Ambrisentan in IgA NephropathyThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06989359Phase 2 Study of ADX-038 in Complement-Mediated Kidney DiseaseADARx Pharmaceuticals, Inc.
- RECRUITINGPHASE1NCT07054684Study of BHV-1400 in IgA NephropathyBiohaven Therapeutics Ltd.
- ENROLLING BY INVITATIONEARLY PHASE1NCT07135219A Study of Cizutamig in Patients With Immunoglobulin A NephropathyPeking University First Hospital